100299-08-9
100299-08-9
Chemical Structure
Pemirolast potassium
Synonym(s): TWT-8152; BMY 26517
- CAS No.: 100299-08-9
- Formula:C10H7KN6O
- Molecular Weight:266.30
IUPAC Name: potassium 5-(9-methyl-4-oxo-4H-pyrido[1,2-a]pyrimidin-3-yl)tetrazol-2-ide
InChIKey: NMMVKSMGBDRONO-UHFFFAOYSA-N
SMILES: O=C1C(C2=N[N-]N=N2)=CN=C3N1C=CC=C3C.[K+]
Biological Activity: Pemirolast potassium is an orally active antiallergic agent. Pemirolast potassium attenuates Paclitaxel (HY-B0015) hypersensitivity reactions. Pemirolast potassium can be used for bronchial asthma and conjunctivitis research[1]-[5].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Pemirolast potassium | 99.99% | Pemirolast potassium is an orally active antiallergic agent. Pemirolast potassium attenuates Paclitaxel (HY-B0015) hypersensitivity reactions. Pemirolast potassium can be used for bronchial asthma and conjunctivitis research-. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
Structural Analogs
-
Similarity Score 0.85
HY-137863Pemirolast -
Similarity Score 0.54
HY-75267Paliperidone impurity 9 hydrochloride -
Similarity Score 0.54
HY-Z10465Paliperidone impurity 14 -
Similarity Score 0.53
HY-W416427Paliperidone impurity 9 -
Similarity Score 0.52
HY-14254AROlprinone (Standard) -
Similarity Score 0.52
HY-14254Olprinone Hydrochloride -
Similarity Score 0.52
HY-W1125143,6-Di(pyridin-3-yl)-1,2,4,5-tetrazine -
Similarity Score 0.51
HY-W10497891,3-Di(1H-tetrazol-5-yl)benzene -
Similarity Score 0.51
HY-157139ALP/Carbonic anhydrase-IN-1 -
Explore the MedChemAI to find more analogs
References
- [1]. Kawashima T, et al. Inhibitory effect of pemirolast, a novel antiallergic drug, on leukotriene C4 and granule protein release from human eosinophils. Int Arch Allergy Immunol. 1994;103(4):405-9. [Content Brief]
- [5]. Tatsushima Y, et al. Pemirolast reduces cisplatin-induced kaolin intake in rats. Eur J Pharmacol. 2011 Jul 1;661(1-3):57-62. [Content Brief]
